NRX Pharmaceuticals, Inc. Proceeds from Related Party Debt
NRX Pharmaceuticals, Inc. (NRXP) reported Proceeds from Related Party Debt of $23.46 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-21.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRelatedPartyDebt · last filed 2021-05-21
- NRX Pharmaceuticals, Inc. proceeds from related party debt for the quarter ending 2021-03-31 was $23.46K, a 82.32% decline year-over-year.
- NRX Pharmaceuticals, Inc. proceeds from related party debt for the quarter ending 2020-12-31 was $139.09K, a 56.38% increase year-over-year.
- NRX Pharmaceuticals, Inc. proceeds from related party debt for the quarter ending 2020-09-30 was $72.58K, a 39.68% decline year-over-year.
- NRX Pharmaceuticals, Inc. proceeds from related party debt for the quarter ending 2020-06-30 was $136.69K, a 49.72% decline year-over-year.
- NRX Pharmaceuticals, Inc. proceeds from related party debt for fiscal 2020 was $481.01K, a 0.03% decline from fiscal 2019.
- NRX Pharmaceuticals, Inc. proceeds from related party debt for fiscal 2019 was $481.14K.
- NRX Pharmaceuticals, Inc. proceeds from related party debt for fiscal 2018 was $0.00.
| Period end | Proceeds from Related Party Debt 3 month | Proceeds from Related Party Debt 6 month | Proceeds from Related Party Debt 9 month | Proceeds from Related Party Debt 12 month | Proceeds from Related Party Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2021-03-31 | $23.46K 10-Q · filed 2021-05-21 | $162.54K derived: sum of 2 quarters · filed 2021-05-21 | $235.13K derived: sum of 3 quarters · filed 2021-05-21 | $371.82K derived: sum of 4 quarters · filed 2021-05-21 | |
| 2020-12-31 | $139.09K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | $211.67K derived: sum of 2 quarters · filed 2021-05-14 | $348.36K derived: sum of 3 quarters · filed 2021-05-14 | $481.01K 10-K/A · filed 2021-05-14 | |
| 2020-09-30 | $72.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $209.27K derived: sum of 2 quarters · filed 2020-11-16 | $341.92K 10-Q · filed 2020-11-16 | $430.86K derived: sum of 4 quarters · filed 2021-05-21 | |
| 2020-06-30 | $136.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $269.33K 10-Q · filed 2020-08-14 | $358.28K derived: sum of 3 quarters · filed 2021-05-21 | $478.61K derived: sum of 4 quarters · filed 2021-05-21 | |
| 2020-03-31 | $132.65K 10-Q · filed 2021-05-21 | $221.59K derived: sum of 2 quarters · filed 2021-05-21 | $341.92K derived: sum of 3 quarters · filed 2021-05-21 | $613.79K derived: sum of 4 quarters · filed 2021-05-21 | |
| 2019-12-31 | $88.94K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-14 | $209.28K derived: sum of 2 quarters · filed 2021-05-14 | $481.14K derived: sum of 3 quarters · filed 2021-05-14 | $481.14K 10-K/A · filed 2021-05-14 | |
| 2019-09-30 | $120.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $392.20K derived: sum of 2 quarters · filed 2020-11-16 | $392.20K 10-Q · filed 2020-11-16 | $392.20K derived: sum of 4 quarters · filed 2020-11-16 | |
| 2019-06-30 | $271.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $271.87K 10-Q · filed 2020-08-14 | $271.87K derived: sum of 3 quarters · filed 2020-08-14 | $271.87K derived: sum of 4 quarters · filed 2020-08-14 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-05-15 | $0.00 derived: sum of 3 quarters · filed 2020-05-15 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $0.00 derived: sum of 2 quarters · filed 2020-03-30 | $0.00 10-K · filed 2020-03-30 | $690.00K 10-K · filed 2019-03-15 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $0.00 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-14 | ||||
| 2017-12-31 | $147.63K 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |